EGFR and neoplasm: However, unlike other tumour types where inhibition of wild-type EGFR by monoclonal antibodies or tyrosine kinase inhibitors (TKIs) is beneficial [14–17], EGFR-targeted therapies in TNBCs have shown variable and unpredictable clinical responses (1.7% to 38.7%) [18–22].